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This paper describes the intravenous (IV) fluids requirements being developed for
medical care during NASA’s future exploration class missions. Previous research on IV
solution generation and mixing in space is summarized. The current exploration baseline
mission profiles are introduced, potential medical conditions described and evaluated for
fluidic needs, and operational issues assessed. We briefly introduce potential methods for
generating IV fluids in microgravity. Conclusions on the recommended fluid volume
requirements are presented.
I. Introduction
The Vision for Space Exploration outlined a new direction for NASA, consisting of missions unlike those
accomplished before. These missions will return astronauts to the Moon and test the technologies required for Mars
missions. The International Space Station (ISS) will be used as a test bed for some of these new technologies.
NASA’s Exploration Systems Architecture Study presents the Design Reference Missions (DRMs) that are being
used to facilitate the derivation of requirements for the essential technologies. These DRMs include missions to ISS,
Lunar Sorties, Lunar Outposts, and Mars Exploration.1
These longer duration missions increase the likelihood of a medical incident and thus the need for medical fluids.
The Patient Condition DataBase (PCDB) contains a list of over 400 medical conditions that may present and require
treatment during ISS missions.2 These conditions are a subset of the total possible conditions that could be
encountered during long duration, Extra-Vehicular Activity (EVA) intensive, exploration missions. Of the 442
conditions, approximately 115 may require medical fluids during the course of treatment. Terrestrial treatment
would typically include fluids such as Normal Saline (NS) (0.9% NaCl), 5% Dextrose, Lactated Ringer’s, or whole
blood. Operational constraints, such as mass limitations and lack of refrigeration, may limit the type and volume of
such fluids that can be carried onboard the spacecraft. Representative conditions that would require fluid treatment
include major bone fracture, burns, and acute anemia. These conditions are described in detail later in this paper.
Choosing a technology to generate sterile water for injection and produce intravenous fluids requires balancing
capabilities with mission and medical requirements. For example, the type, volume, and timeline over which IV
fluids are required are key drivers in selecting an appropriate technology. Additionally, the system must operate in
various gravity environments, such as microgravity, lunar gravity, and Martian gravity, while also functioning in
earth normal gravity for testing and verification. Thrusting events also produce an effective gravitational level and
could possibly occur during fluid production. Successful operation requires maintaining sterility. Some
technologies might be sealed until use, requiring only seal integrity, while other systems may require internal
recirculation or periodic maintenance to ensure proper operation. Diagnostics will likely be required to verify
proper operation of the system. Crew time is always an issue, and may be especially important in an emergency.
Any system must be relatively simple to use, safe, and reliable.
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A. Previous Research
In the late 1980s and early 1990s, NASA conducted a detailed investigation to determine the possibility of
producing IV fluids on orbit as part of the Health Maintenance Facility of the Space Station Freedom Program. The
Johnson Space Center (JSC) led this effort, which included contracts with Krug International, Sterimatics, and
Baxter, culminating in a flight experiment on STS-47 from 9/12/1992 - 9/20/1992. The final decision at the time
was not to produce sterile water on Space Station Freedom, but to use prepackaged IV fluids. No flight-ready
hardware was fabricated for sterile water production. This section briefly summarizes the results of those earlier
efforts.
1. IV Fluids Requirements White Paper
Creager of Krug Life Sciences (1991) evaluated six scenarios requiring fluids for medical treatment.3 Fluid
volumes were calculated for each scenario using seven types of solutions. The volume required to cover a particular
scenario ranged from 11 L to 90 L, averaging 37 L. The total volume required to treat all individual scenarios
envisioned for a mission and the minimum volume required to any one individual scenario in a mission were also
calculated. The total volume of the 7 types of solutions required to cover one incident of each scenario was 220 L,
while 141 L was the maximum required to cover any single scenario. (The report suggested that the minimum was
123 L but there was an 18 L error in the calculations for the minimum amount of Normal Saline required.)
2. Sterile Water for Injection System
Krug International, as lead contractor for the Health Maintenance Facility on Space Station Freedom, contracted
with Sterimatics Corporation to develop a Sterile Water for Injection System (SWIS) as part of a system to produce
IV fluids. The SWIS was a filter/adsorption based technology to produce Water for Injection (WFI). The design
goal was to convert ISS “hygiene water,” which has a lower quality than potable water, to produce WFI. System
requirements included producing at least 6 L of WFI at 6 L/hr with a sterile shelf life of 90 days, utilizing a filter
with a minimum shelf life of 1 year. As developed, the SWIS had a dry mass of 2 kg and produced 9 L of WFI from
water containing contamination levels 10 times the ISS potable water specification. Testing indicated that at least
20 L of WFI could be produced from potable water. The SWIS was flown on STS–47 in September 1992 as part of
the Fluid Therapy System on the Spacelab–J (Spacelab–Japan).
3. Zero Gravity IV Mixing System
Krug International contracted with Baxter Healthcare to produce a system for mixing constituents in custom IV
bags. Baxter worked on developing methods to mix both powders and concentrates, but was unable to overcome
problems in mixing powders.4 The development was constrained by a passive system requirement, utilizing only
water pressure to produce the mixing. Baxter conducted experiments with a dyed concentrate and observed a low
degree of mixing, with the heavier, dyed concentrate located on the bottom of the bag in 1g testing. No quantitative
mixing studies were completed in normal or microgravity. Subsequent analysis and tests have demonstrated that
these mixing techniques can easily be gravity-driven and care must be taken not to interpret those results as a
testament to their effectiveness in microgravity.4
4. STS-47 Fluid Therapy System
The Spacelab–Japan Module flew on STS–47 during September 1992. One of the experiments was the Fluid
Therapy System (FTS), testing the equipment and procedures developed thus far for IV generation. The FTS
utilized the adsorption filters developed by Sterimatics to produce the WFI, and the IV bags and mixing method
developed by Baxter to produce the final solutions. An infusion pump administered a saline solution into a
mannequin arm to complete an end-to-end system test. The degree of mixing was not quantified on orbit, nor was
the solution frozen or fixed in any fashion to preserve the state of mixing on orbit. While later analysis on Earth
showed that the final solution met the tolerance criteria for solution concentration (±5% of desired concentration),
that determination was only a validation of the amount of solute in the final solution, not a verification of achieving
the in-flight mixing requirements because vibrations from landing and handling as well as molecular diffusion
would have easily homogenized the sample by the time the post-flight analysis was performed. Ground testing of
the produced WFI also concluded that it exceeded the maximum Total Organic Carbon requirement. It has been
speculated that the source of this carbon was from the IV bags themselves, although channeling in the adsorption
system is also possible. In addition, Astronaut Mae Jemison observed serious bubble problems during the
experiment.
B. Objectives of this Paper
This paper focuses on describing the requirements for IV fluids for NASA’s missions and presenting key issues
in developing any IV generation system. It introduces potential generation technologies, and presents conclusions on
whether generating IV fluids on orbit is preferable to flying pre-packaged supplies. The profiles of expected
missions, as outlined in the Exploration Systems Architecture Study (ESAS) Design Reference Missions (DRM), are
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described and analyzed for potential emergency medical care needs. These missions are still very early in the
planning stages, so detailed equipment requirements have not been developed, and mission scenarios may change.
Much of the expected medical care needs are based on current and past mission requirements, as well as past
advanced planning.
Potential medical conditions are analyzed to determine whether IV fluids might be required and the approximate
quantity. The analysis is on a layman’s level to give a rough estimate of fluids requirements. Some of the key
questions and requirements that an IV generation system must meet are elucidated. Questions include quantities
required, production rate requirements, quality requirements, and in-space operation. Some potential technologies
are summarized. Conclusions are drawn about whether produced or stored IV fluids are more appropriate for a
given DRM.
II. Medical Conditions Requiring Fluid Treatment
The ISS PCDB was analyzed to determine which potential conditions require fluid treatment.2 Of the 442 listed
patient conditions that may be encountered while onboard the ISS, approximately 115 may require intravenous fluid
treatment. These conditions may also occur on other exploration missions, possibly with a different probability of
occurrence. These possible conditions have been grouped into major areas where the reason for fluid treatment is
approximately the same. The required treatment is developed only at the top level, following standard medical
practices. Individual patient situations and physician preference may change the preferred fluid treatment.
From the point of view of providing WFI for exploration missions, the most demanding scenario is treating a 100
kg male. While NASA does not have official astronaut weight standards, the maximum height allowed is 76 in, and
the maximum Air Force pilot weight at 76 in height is 102 kg. The main goal in this study is to determine the
overall volume of fluids required, and which solutions are generally preferred. These results will be used to define
and size an IV fluid generation system. The Space Medicine Division will determine actual fluid requirements for
an operational system.
A. Severe Burn
Serious burns increase capillary permeability, causing fluid to shift from the vascular system into the
surrounding interstitial space. This shift occurs in thermal burns of 2nd and 3rd degree, as well as severe chemical
and radiation burns. Fluid treatment is based on the size of the burned surface area, and is the same for all types of
burns. Burn surface area calculations include areas with 2nd and 3rd degree burns, but not 1st degree burns. Burns
covering more than 15% Total Body Surface Area (TBSA) require fluid treatment to replace the lost intravascular
volume. In these cases, prompt fluid treatment is critical to survival. There are many guidelines for fluid treatment,
but the most widely recognized is the Parkland formula6. Most guidelines recommend fluid treatment for 24 hrs, and
then lesser treatment for the next 24-48 hours, with fluid intake levels approaching normal maintenance
requirements.
For this paper, the recommendations contained in The United States Naval Flight Surgeon Handbook7 will be
utilized and were based on recommendations from Brooke Army Medical Center. The Handbook recommends 2-4
mL/(kg %TBSA) of Lactated Ringer’s (LR) in the first 24 hrs, with half of that amount given in the first 8 hrs.
Recommendations for the second 24 hours are 0.5 mL/(kg %TBSA) of 5 % albumin in Lactated Ringer’s (200 cc
25% albumin in 800 cc of LR) and D5W at 2-4 mL/(kg %TBSA), which is the same fluid hourly infusion rate as the
first 24 hours. Albumin is not recommended, however, for inclusion in Exploration missions due to uncertain
efficacy, storage life concerns, and radiation concerns.
A 100 kg male with a 40% burn surface area would require 16 L of LR in the first 24 hours according to the
Parkland and Naval formula (8-16 L Naval), with 8 L given in the first 8 hours. The second 24 hours would require
8-16 L of D5W and 2 L of 5% albumin according to Naval guidelines. As mentioned above, NASA will not plan to
include the albumin for exploration class missions. The D5W rate is adjusted by monitoring urine output, but these
tests may not be available on exploration missions. Fluid treatment beyond 48 hours would only be required if the
patient is physically unable to eat and drink. The maximum total fluid requirements would be 16 L of LR and 16 L
of D5W, for a total of 32 L.
B. Acute Anemia
Acute anemia due to blood loss requires fluid treatment to maintain the intravascular volume. The blood loss
can occur from a major laceration, puncture wound, or other causes. Crystalloids are the appropriate treatment for
moderate volume loss, but blood transfusions should normally be considered after 2 L of crystalloids. The general
terrestrial rule of thumb is 1 unit of blood for every 3 units of crystalloid. We made the assumption for this study,
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however, that blood would not be carried on board. Hemoglobin-based oxygen carriers (HBOCs) are a potential
alternative for whole blood in cases of severe blood loss, assuming a sufficient supply while the body regenerates
the red blood cells. Blood loss of 40% or greater (Class IV shock) requires prompt resuscitative measures to avoid
patient demise.
Acute anemia generally utilizes only 2 L of crystalloids before considering blood or HBOC transfusion, although
for the 100 kg male 3 L of crystalloids would provide the same dilution. Normal Saline is the most commonly used
solution in emergency rooms. If the hemoglobin level is allowed to decrease from 15 g/dL to 7 g/dL without
oxygen-carrier transfusion, 53% of the blood volume could be replaced with fluid. A 100 kg male has 7.1 L of
blood, compared to the typical 70 kg male with 5 L of blood. These volumes do not account for any possible
changes due to chronic hypogravity or hypoxic cabin environments.
A 100 kg male could receive 4 L of fluid while maintaining a hemoglobin concentration above 7 g/dL, and 5 L
of fluid and maintain a hemoglobin concentration of 5 g/dL. Because crystalloids tend to leave the vascular system
and diffuse to the interstitial volume, additional fluid is required to maintain proper intravascular volume while the
patient recovers. Assuming a 30% intravascular volume loss is acceptable, a maximum 66% blood loss to maintain
sufficient hemoglobin, and a 20% intravascular crystalloid retention, a maximum 12 L of Normal Saline would be
required for the worst case. A patient would be physically unable to survive without an oxygen-carrier transfusion if
the blood loss was more severe. Only 3-5 L would be delivered immediately, with the remaining amount delivery as
the crystalloid leaves the intravascular volume and blood pressure drops. Infusing 12 L of crystalloid could
introduce other serious problems, and should be considered an absolute worst case, to be used only if blood or
HBOCs are not available.
C. Drug Delivery
Certain medications specify delivery by IV fluid. This restriction is often due to the need for a prolonged
delivery timeline, and may be avoided in some emergencies by multiple delayed injections. The ability to provide
drugs by IV does have procedural advantages in requiring less human involvement, eliminates multiple injection
sites, and provides versatility in varying the drug introduction rate. Currently, 4 drugs that are on the ISS require
some volume of IV fluid for delivery, and 4 more are under consideration. Longer duration missions with no chance
of timely transport will presumably carry more such drugs. There are many conditions in the PCDB that may
require IV drug delivery, from severe conditions such as cardiac arrest to less life-threatening conditions such as
various forms of infections. To provide a quick method for administering medicines if needed, starting an IV line
upon admission is standard procedure in most terrestrial emergency rooms. Normal Saline is often preferred as it
avoids any potential problems with excess glucose. Lactated Ringer’s cannot be injected at the same site with blood
because of interactions with stabilizing chemicals.8,9 Many of the drugs requiring IV delivery would be administered
in one dose, or given over a relatively short duration. They would require only 1-2 L of fluid for injection.
Conditions requiring long-term IV drug delivery typically require 1-2 L per day, with Normal Saline as the generally
preferred diluent.
D. Bone Fracture
Fractures of major bones of the body such as the femur, radius, or hip could require fluid treatment. Major blood
vessels could be severed, resulting in blood loss and acute anemia. The blood loss is generally internal to the body.
Treating severe fractures requires open reduction and realignment; these procedures are simple enough for
consideration on exploration missions but this minor surgery entails additional blood loss. A fracture of the femur is
more severe since major arteries are subject to severing. A femur fracture can cause internal blood loss can be as
high as 2-3 L, with compartment syndrome a major concern..
Fractures of the long bones in the arms and lower legs can cause internal blood loss and sequestration, but
generally do not require fluid treatment. A worst-case scenario for these fractures also includes open reduction and
requires up to 2 L of NS. Fractures of the femur can be far more severe. If a fasciotomy is not attempted to reduce
intracompartmental pressure and avoid tissue necrosis, the treatment fluid volume required is bounded by the need
to prevent excessive hemodilution while preserving adequate blood pressure. This internal blood loss limit is lower
than that of the external blood loss case discussed in regards to acute anemia. An estimate of the maximum amount
of fluid required to treat a femur fracture without a fasciotomy is 8 L of NS (again, assuming blood is not available
on board).
E. Fluid Maintenance
Humans require water to replace that lost during the day to the environment. Water is released through bodily
waste, through the skin as a heat regulation mechanism, and through the lungs due to evaporative losses during
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breathing. Normally water replacement is 2/3 from drink and 1/3 from food. A patient physically unable to eat or
drink must have water, electrolytes, and caloric requirements replaced intravenously. The most common method to
calculate requirements is the Holliday-Segar Method.10 This method is widely accepted, but was developed from
pediatric studies in patients up to 70 kg in weight, and has not been verified for low-pressure environments.
Hypogravity is known to at least temporally affect body fluid levels, and a low-pressure cabin might affect the fluid
loss through changes in the respiration and perspiration rates. For humans >20 kg, the daily requirements are10
• 1500 kcal + 20 kcal/kg over 20 kg,
• 1 cc water/kcal,
• 3 mEq Na/100 cc water,
• 2 mEq K/100 cc water, and
• 2 mEq Cl/100 cc water.
A 100 kg male would require 3.1 L of fluid per day according to the Holliday-Segar formula. The solution
would typically be D5 ½ NS + 20 mEq KCl/L. This should continue for not longer than 10 days before alternative
treatments are implemented due to the lack of calories and other trace chemicals. Assuming the patient would be
treated for no longer than 14 days worst case, 44 L of fluid would be required.
III. Exploration Mission Fluid Requirements
NASA is currently considering and planning a wide variety of missions that vary in duration from several days
to many months in the case of a Martian voyage. The missions also differ from one another by the ease with which
a patient can be returned to earth. These two factors, duration and ease of return, dictate different fluid generation
and mixing requirements for each mission, even for the same set of patient conditions. There will also be
considerable differences in the mass allotted for medical supplies to treat patient conditions. In this section, we
outline treatment timelines and fluid needs for four different missions, one to ISS, a lunar visit, a lunar habitat, and a
trip to Mars.
A. Fluid Requirements for ISS
The long duration nature of the mission allows for some flexibility in the treatment timeline. The time, space,
and potentially the supplies required are available to treat the patient in-situ. Patients could be allowed to stabilize
after major injury prior to transport to earth. The transport time would be a matter of hours, but loading time may be
extended due to issues of moving the patient. For a worst case condition, the patient could be stabilized for up to
two weeks prior to transport.
The critical fluid patient conditions for an ISS mission are severe burns, acute anemia, major fractures, and IV
maintenance. It is expected that most medical events would involve only one patient, but a major fire could
encompass multiple crewmembers. The potentially long stabilization time makes maintenance the largest potential
fluid requirements event. Based on more detailed analysis5, Table 1 illustrates the ISS fluid requirements.
Burn (2 patients) Major Long
Bone Fracture
Trauma with
Acute Anemia
Illness with Drug
Delivery
Trauma or
Illness with
Maintenance
24 L LR
77 L D5KS
8 L NS 12 L NS
9 L D5KS
16 L NS 4 L NS
9 L D5KS
Table 1: Fluid requirements to treat two crewmembers with major injuries/illnesses on the ISS.
B. Lunar Sortie
The short duration of the mission limits the potential time for patient stabilization prior to Earth return. It also
lessens the chance of multiple events during the mission. A maximum of 7 days can be spent on the surface, and
transport back to Earth can occur from any site at any time in 5 days or less. Medical events that happen during the
initial transit to the moon can utilize the free-return abort mode as in Apollo 13, limiting the maximum total
treatment time to 6 days for an event in the early stages of the mission when a direct-return is not possible. The
limited supplies in these missions will restrict the time allowed for stabilization prior to starting return.
Requirements in this document assume that transport will begin 24 hours after any major incident.
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The critical fluid patient conditions are burns, acute anemia, major fracture, and maintenance. The maintenance
fluid requirements are lower than for the ISS mission due to the fewer days of treatment (6 versus 14). Severe
illness or infections that would require long-term drug delivery are not considered likely on these short duration
missions if astronauts are effectively pre-screened for health conditions.
The detailed analysis given in reference [5] yielded the following estimate of Lunar Sortie requirements.
Burn (1 patient) Major Long Bone
Fracture
Trauma with Acute
Anemia
Trauma or Illness
with Maintenance
16 L LR
28 L D5KS
8 L NS 12 L NS
9 L D5KS
2 L NS
6 L D5KS
Table 2: Fluid requirements to treat two crewmembers with major injuries/illnesses on the Lunar Sortie.
C. Lunar Outpost
The lunar habitat missions currently envisioned will require a crew of 4 occupying an outpost for up to 6 months.
A continuous human presence on the moon will be accomplished by crew rotation. The supplies available for
medical treatment may well be increased over the short duration missions, but exact parameters have not been
established. The vehicles developed for the lunar sortie will be used for crew rotation. This implies a maximum 5
days from return decision to touchdown. One of the purposes of this class of missions is validating technologies
required for Martian exploration, including medical capabilities. These missions are the best opportunities for
evaluating medical technologies and procedures for Mars missions when no return will be possible.
The treatment timeline is similar to that outlined for the ISS. The facilities available will allow time for patient
stabilization prior to transport if that is the best course of action. Due to the relatively long transportation time with
limited facilities, in-situ treatment could produce better outcomes than evacuation. Requirements in this document
envision that a patient could stabilize for up to 14 days before a 5-day evacuation. Not considered are potential
mission scenarios with an extended duration rover away from the habitat for several days. Table 3 gives the
requirements.5
Burn (2 patients) Major Long
Bone Fracture
Trauma with
Acute Anemia
Illness with Drug
Delivery
Trauma or
Illness with
Maintenance
24 L LR
92 L D5KS
8 L NS 12 L NS
9 L D5KS
16 L NS 4 L NS
9 L D5KS
Table 3: Fluid requirements to treat two crewmembers with major injuries/illnesses during a Lunar Habitat
mission.
D. Mars Exploration
Mars exploration is planned as a conjunction-class mission, with a 6 month transit to and from Mars, and an 18
month stay. A crew of 6 will be included on this 2.5 year mission. No early return is possible in the case of an
emergency. All medical conditions must be treated on-site with available resources. This mission will include
extended time in both microgravity and 0.38 g. A pre-deployed surface habitat, and a pre-deployed Mars Lander
will precede crew launch. Separate medical equipment could be provided for in both the transfer vehicle and the
habitat.
The inability to transport injured crew to Earth facilities requires that all medical conditions, except those at the
very beginning or end, must be treated to recovery, supply exhaustion, or death of the patient. The total mission
length is similar to the combination of 2 continuous ISS expeditions in microgravity and 3 continuous lunar habitat
expeditions in partial gravity. The medical conditions that may be encountered on the Martian surface are similar to
those for the lunar habitat. The microgravity transit will presumably not include any construction activities like on
ISS, but could include repair EVAs. Mars Exploration Requirements are shown in Table 4.
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Burn (2 patients) Major Long
Bone Fracture
Trauma with
Acute Anemia
Illness with Drug
Delivery
Trauma or
Illness with
Maintenance
24 L LR
148 L D5KS
8 L NS 12 L NS
16 L D5KS
22 L NS 4 L NS
16 L D5KS
Table 4: Fluid requirements to treat two crewmembers with major injuries/illnesses during a Mars mission.
E. Summary of Fluid Requirements
Within each of the missions, several scenarios were evaluated for the overall medical fluid requirements. These
scenarios included a single event, a single major event with one minor event, a single major event with a burn event,
and other combinations described in reference [5]. Total mission fluid requirements were then developed based on
treating various combinations of medical events. During this development, it was recommended that Lactated
Ringer’s and Normal Saline be considered nearly interchangeable electrolytes to reduce the overall volume
requirements.
Table 5 gives the final recommended volumes for the various missions. The longer duration missions include
fluid to treat multiple medical events. Mass constraints may limit the fluid provided on missions, so a minimum
fluid recommendation is also included. Normal Saline, whether premixed or mixed on-board during an emergency,
is the only electrolyte included in the minimum recommendations. The ISS minimum recommendation would be
sufficient to treat any one medical event excluding maintenance fluids (dextrose is carried to meet the 48 hour fluid
requirement for burns). The lunar sortie minimum recommendation would cover any one event except a burn event,
and excluding maintenance fluids. It would provide the minimum volume recommendations for a 100 kg patient
with 30% burns, although not the caloric intake provided by D5KS and not any fluids beyond the first 48 hours. The
lunar habitat minimum recommendation would treat any one event, excluding maintenance requirements. The
minimum recommended for a Mars mission is more generous. It would cover the initial fluid requirements of the
burn event with two patients, and the initial requirements of any other one event. Maintenance fluids for a total of
15 days are also included to treat the 3 potential patients.
Mission
Recommended Event
Coverage
Fluid Volume
Recommendation
Minimum Fluid
Recommendation
ISS
Any one minor event
and any one major
event
20 L LR
20 L NS
86 L D5KS
126 L total
24 L NS
24 L D5KS
48 L total
Lunar Sortie Any one event
8 L LR
8 L NS
28 L D5KS
44 L total
12 L NS
12 L total
Lunar Habitat
Any one minor event
and any one major
event
20 L LR
20 L NS
101 L D5KS
141 L total
24 L NS
24 L D5KS
48 L total
Mars Exploration
Any two minor events
and one burn event
34 L LR
34 L NS
180 L D5KS
248 L total
36 L NS
69 L D5KS
105 L total
Table 5: Final fluid volume recommendations for exploration missions.
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IV. Considerations for Creating Water for Injection
When developing a Water For Injection (WFI) production system for NASA’s exploration missions, the unique
operational environment raises additional challenges not encountered when developing a ground-based system and
requires special considerations. In addition, the initial water source supplied to the system may have important
differences from the water that ground-based systems typically employ. The gravity level, radiation level, and
sealed environment all raise concerns about microbial contamination and how to maintain sterility of the system in
conditions not previously encountered by WFI systems. These concerns are in addition to the normal NASA
concerns on minimizing weight, volume, and power, while maximizing reliability.
A. Water Quality Requirements
The requirements for WFI and sterile WFI are set out in the United States Pharmacopeia (USP).11 That document
contains specific requirements that must be met, as well as general requirements that can be difficult to quantify.
The general, unquantified requirements could be problematic with a unique system specific to NASA’s needs.
NASA’s needs may well be better met by a new type of system, but defining equivalent performance of existing
systems is a challenge. As an example, the USP standard requires that source water meet Environmental Protection
Agency (EPA) potable water standards. The EPA does not have standards on all possible contaminates, such as
iodine and silver because these biocides are not normally used in public water systems. Biocides are not allowed in
water for injection and must be removed. Reference [5] discusses in detail the various agencies and regulations
governing water quality and allowed contaminant levels in water to be used for different purposes.
B. Water Sources
While using potable water as the source to generate WFI is obvious, other potential sources exist. Short duration
missions could use fuel cells, such as in the Shuttle, to generate high purity water. Oxygen generation via
electrolysis for moderate duration missions uses potable water with an additional deionizing bed to remove the
iodine biocide. This product water could also be used to generate WFI. A generic emergency water source to be
used for oxygen generation, medical emergencies, or replenishing potable water stores may be a viable option for
moderate to long duration missions. Water obtained from in-situ resource utilization would presumably go through
processing to bring quality up to potable water standards.
Potable water on the ISS is used for drinking and hygiene. NASA potable water must meet requirements as set
out in NASA SSP 4100012, which is different than EPA standards. There is some overlap in the two standards, but
NASA’s standards cover contaminants specific to spacecraft water, and do not have requirements to eliminate
contaminants commonly found in public water systems. Overlapping contaminant standards are generally stricter in
NASA’s requirements, but this is not true for all substances.
Oxygen production requires higher purity water than NASA potable water. The Oxygen Generation System
(OGS) flight hardware generates oxygen via electrolysis and was flown to ISS on STS-121 this year. This system is
designed to utilize NASA potable water provided by the Water Recovery System. An internal deionizing bed
removes the iodine biocide, as well as other ions13. This treated water remains internal to the OGS, and is not
normally available for other uses.
C. Production Timeline
The choice of a system to produce WFI is critically tied with the timeline over which water would be available.
Systems that produce water more slowly must have some sort of stored capacity to meet potential requirements for
an initial bolus in the case of an emergency. Such a contingency is at odds with the general NASA philosophy to
eliminate the mass of stored water. Production timelines for various systems are described below.
An on-demand system would require a high production rate in order meet the initial needs, on the order on 4
L/hr. This high production rate may preclude certain technologies from consideration. Stowing limited supplies on
the order of 2-10 L to handle the initial needs, and then producing fluids at a moderate rate to keep the supplies
replenished is an alternative to a large capacity on demand system. Typical IV fluid maintenance rates are 4 L/day,
although certain conditions could require more fluids in the short term. An online system available for production at
any time, or a limited use system that produces a fixed quantity of fluid before requiring consumable replacements is
another option. Cartridge-type systems use consumables to remove and store the contaminants. Cartridge systems
typically treat limited quantities of fluid, on the order of 10 L. Such systems could be developed for one time use,
where a cartridge is rated to purify a prescribed volume of fluid and is also rated for a limited duration of dry, sterile
storage.
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D. Solution Production
The final product for ultimate use is a medical solution. This requires adding and mixing the constituents, such
as sodium chloride, glucose, or other pharmaceuticals. The physical state of the constituents directly affects the
mixing method and indirectly affects the water production method. The mixing time also influences the delivery
timeline. Time to treatment can be critical in an emergency. To fit within a therapeutic window, longer mixing
times reduce the time available for WFI production. A long mixing time may require a large capacity production
system to decrease the WFI production time. Mixing time is less critical for a system with emergency stores. The
method appropriate for mixing the solution to final form is the subject of an ongoing project at GRC.14
E. Hypogravity Production Challenges
Microgravity poses operational challenges for any fluid system. Potential problems in an IV system arise in all
phases of operation, from production to storage to handling. There are also potentially unique sterility issues arising
from microgravity operation. Addressing challenges induced by hypogravity issues should be tackled early in the
design phase, rather than attempting to add ad hoc solutions later in the development process. Design challenges
due to altered gravity are frequently of such magnitude that they can only be effectively addressed in the design
phase. In general, partial gravity systems are somewhat easier to design and test, but still require careful analysis. A
more detailed discussion of the difficulties hypogravity imposes is given in reference [5], while a summary is
provided below.
Many of the microgravity fluids issues arise when a liquid-vapor interface is present. The interface may be
present by design, or as an off-nominal condition. All production methods are potentially affected by the presence
of bubbles in the system. The location of bubbles in microgravity is much more difficult to predict because, unlike
normal gravity, the system has no top. Thus, mitigating bubble problems is harder in microgravity. Bubbles can
cause pump problems such as loss of prime, which could be mitigated by less susceptible positive displacement
pumps. Adsorbent media such as charcoal filters or ion-exchange resins are only effective when water is able to
pass through them. Such media are rendered ineffective when the gas bubbles effectively channel the liquid flow
around a dry volume, or could result in a stagnant flow, which can then become a bacterial breeding ground. Filters
and membranes can be rendered ineffective for similar reasons.
Many ground-based systems, and some proposed microgravity systems have a storage vessel for limited WFI
storage. Storage may not be required for an on-demand system, but a system designed for gradual replacement may
perform better by storing small volumes of WFI prior to filling IV bags. Filling, venting, and removal from
containers in microgravity is complicated by ensuring the proper location of the liquid and vapor present. Capillary
devices are often used for liquid management.
Using devices at various places in the system to trap and remove the bubbles could alleviate Microgravity
handling challenges. Bubble traps could remove inlet bubbles from source water prior to entering the WFI
production system, prior to any storage container, the mixing device, and/or prior to actual use. These traps could be
used constantly, such as the inlet trap, be required only during a priming operation, or require monitoring and action
if the closed system is breached and a bubble enters the system. Some production methods, such as distillation, may
require more rigorous bubble control methods. There may also be microgravity-handling issues with particulates in
the system. The filter-based technologies may have particulates released from the media that may be more readily
transported in microgravity, depending on filter orientation.15
Maintaining sterility of a medical water generation system is critical to its ultimate performance. This task is
challenging under normal gravity, and presents some unknown issues in microgravity. The environmental effects of
microgravity and increased radiation may cause differences in microbial growth, as well as potentially increase
mutation. Cell culture experiments on Shuttle and ISS have shown measurable differences in microgravity, but
operational experience on Mir and ISS has not shown noticeable microbial differences with gravity level. It is not
expected that microgravity operation will present any additional sterility challenges.
V. Potential Production Technologies
Table 6 gives a summary of the technologies that could be used to generate WFI during an emergency and for
subsequent maintenance needs.5 (Note that the SBIR level technologies are not included in the table and the reader is
referred to reference [5] for those). Only two technologies are currently approved for WFI, distillation and reverse
osmosis. Unfortunately, both suffer from disadvantages that make them difficult to adapt to spacecraft use.
Distillation requires a large amount of energy, a cooling surface, and gravity or other means of separating the gas
from the liquid. RO, meanwhile needs a relatively high-pressure water source, and faces sterilization issues for
repeated use.
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Currently the technology next closest to meeting USP standards is a combination of filtration (to remove larger
contaminants) and adsorption to remove specific molecular and living species (i.e., viruses). While not yet approved
for parenteral use, vendors are making improvements that may allow this use in the future. Forward osmosis (FO)
could likely be approved for parenteral use, given that RO is approved, but is limited to producing concentrated
solutions and not nearly as flexible as technologies that produce pure water from which the desired solution can be
made. FO may find a niche application in WFI. The remaining three technologies, membrane distillation, osmotic
distillation (which, like FO, can only produce concentrated solutions), and nano-filtration offer some potential
advantages of weight and power, but are still in the development stage and would require more extensive work to
produce WFI in space.
A future trade study is planned to identify, evaluate in more detail, and draw conclusions about these potential
WFI production methods. The trade study will select the method most appropriate for the various DRMs, and
provide estimates of expected performance. Other technologies may be identified during the trade study and
included as well. The potential technologies will be quantitatively evaluated to present a non-biased ranking. The
selection criteria will include parameters such as production rate, sterility, mass, consumables, hypogravity
confidence, operations, and development ease.
Water
Generation
Method
Contaminants
removed
In use now
for WFI
Rate of
generation
Energy
needed for
generation
Sterilization Other needs orlimitations
Distillation Essentially
everything Yes
High; many
gallons per
hr.
13 Wh/liter
May need to
sterilize cold
lines.
Need a cool
surface for
condensation.
Conventional
separation
requires gravity
to work
Reverse
Osmosis
Bacteria,
endotoxins
Viruses
Large molecules
solids
Salts to some
extent
Yes. Also
was tested
by KSC for
space use
and met
most USP
standards
several
gallons/day
Need
pressurized
water (120 psi
or more)
need to
sterilize
membrane and
whole system
periodically
Adsorption
Most
contaminants can
be removed, but
adsorber(s) must
be chosen for
specific
contaminants
No
Depends on
size of
cartridge. 4.5
l/hour is
available
Need low
pressure
water of a
couple psi
cartridge can
be stored
sterile, but only
used once
Current cartridge
can treat 3 liters,
then must be
disposed
Filtration
Bacteria
Endotoxins
Solids
No
Varies with
filter. Ex 0.7
l/m for 5 psi
Need
pressurized
water source
Chemical
treatment or
Disposal
Forward
Osmosis
Same as reverse
osmosis No 0.8 l/hr none
Use once, then
dispose.
Cannot produce
pure water, only
concentrated
solutions.
Membrane
Distillation
Essentially
everything, but
still under
development
No Not yet tested
Lower than
traditional
distillation
Not yet tested
Need a cool
surface for
condensation
Osmotic
Distillation
Essentially
everything No
N/A, but
likely slow Low Not yet tested
No high pressure
as in RO
Cannot produce
pure water, only
solutions
Nano
Filtration
Still in the
experimental
phase – actually
being developed
to cleanse blood
No
N/A, but
similar to
kidney
function
low pressure
fluid needed
N/A –
probably need
to dispose
No large-scale
device ever made
Table 6: Efficacy of various methods of water purification.
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VI. Recommendations
NASA’s Vision for Space Exploration has initiated new efforts to determine what technologies will be required
for exploration of the Moon and Mars, and to define how these technologies will be developed and validated.
Medical requirements and capabilities are being developed as part of this process. In particular, the necessity and
required volumes for medical intravenous fluids are presented in this paper.
Terrestrial hospitals have a wide variety of fluids for medical use, but the mass and storage requirements limit
what NASA may carry. In particular, human blood or blood products cannot be provided on exploration missions
because of limited storage life and refrigeration capabilities. HBOCs are under development as a substitute, but
have not reached sufficient maturity to be included in NASA’s planning at this time. Colloids are also commonly
used for terrestrial medical treatment, but recent research questions the efficacy of colloids over crystalloids. It is
recommended that 3 types of fluids be available for use in NASA’s exploration missions: Lactated Ringer’s (LR),
Normal Saline (0.9 %) (NS), and 5% Dextrose with 1/4 NS and 20 mEq KCl (D5KS). These are the most common
fluids used for burns, trauma and medication, and maintenance requirements respectively. Lactated Ringer’s and
Normal Saline are often considered nearly interchangeable during treatment, and it is recommended that they be
considered fully interchangeable for high-volume medical fluid treatments during exploration missions to reduce the
overall volume requirements. It is also recommended that the medical community evaluate whether the LR and NS
requirements can be met by one electrolyte to further reduce the logistics requirements.
The requirements for medical fluids were developed by evaluating the patient conditions in the PCDB. Five
generic situations were identified to quantify fluid requirements, rather than develop fluid requirements for each
specific condition. These five conditions were 2nd and 3rd degree skin burns, acute anemia, drug delivery, major
bone fracture, and fluid maintenance. Actual medical events can require fluid treatment for several of these generic
conditions. Typical medical events were postulated and analyzed to determine fluid requirements for the various
exploration missions. The maximum fluid requirement scenario for each mission was always a major fire, possibly
injuring 2 crew members, requiring fluid treatment followed by maintenance fluids as the patient(s) recover(s). This
scenario is often considered as either the driver for fluid volume requirements, or so severe as to preclude any
treatment beyond the most basic. Because space exploration has already had several fire or explosion events
(Apollo 1, Apollo 13, and Mir NASA-3), prudence dictates planning for the possibility. Additionally, the planned
low-pressure, oxygen-rich environment in the new spacecraft increases the fire hazard over ISS, and surface
exploration is EVA intensive in a pure-oxygen spacesuit environment.
The recommended fluid volumes are detailed in Table 5. These recommendations should be considered as an
upper bound of what would be required. Mission constraints may limit the supplies provided onboard, while
accepting the subsequent increase in risk. The requirements are similar for the ISS and lunar habitat missions, with
somewhat increased requirements for a Mars Mission. The lunar sortie requirements are substantially less and may
require a different type of fluid production system if fluids are provided.
It is recommended that a system capable of generating 130 L of fluid for two time-separated events should be
developed for ISS and lunar habitat missions. The water generation system should have the capability of generating
100 L of medical water at any time after one minor event, or have the capability to produce and store sufficient
solutions immediately after the first event. Concentrate or powder and associated supplies should be available to
produce 15 L LR, 15 L NS, and 100 D5KS. An 8-hour contingency supply of 6 L LR, 6 L NS, and 2 L D5KS
should be carried as stores. Note that when LR and NS are considered nearly interchangeable as recommended, the
8-hour contingency supply is the same as a 2-hour contingency supply for all of the DRMs. The system would
preferably have the ability to produce new contingency stores with a shelf life of 6 months after a minor medical
event occurs, otherwise new stores will have to be shipped to ensure a sufficient supply. A Mars fluid system would
have the additional requirement of being capable of generating replacement contingency stores with at least a 6-
month shelf life
The lunar sortie has a much reduced volume requirement, and less concern with long-term sterility. It is
probably not realistic to carry an 8-hour contingency supply, so a 1-hour supply of 4 L NS is recommended. The
ability to produce 40 L of solution as 8 L LR, 4 L NS, and 28 L D5KS to handle any one event is recommended.
The solutions produced should meet USP standards to ensure the best possible medical care is being provided.
There is some concern because the USP standards are defined mainly from the process used to produce WFI rather
than quantitative measurements of the final product. This is a problem because the standard process equipment will
not meet NASA’s mass requirements and may not function properly in the space environment. There is an
additional complication because NASA potable water specifications do not match the EPA potable water
specifications that are assumed to be the initial source water. Detailed specifications will have to be developed to
American Institute of Aeronautics and Astronautics
12
ensure the medical water system and the final produced solutions meet the spirit of the regulations if not the specific
process regulations.
Many potential technologies can be utilized to produce the purified water. Many of these technologies are
commercially used to purify liquids in industry, or are being developed in advanced systems for potable water
production. The USP currently states the “Water for Injection is water purified by distillation or by a purification
process that is equivalent or superior to distillation in the removal of chemicals and microorganisms.” To date,
reverse osmosis is the only acceptable alternative to distillation within the USP WFI standards. The USP WFI
standards were developed for production of continuous quantities of at least tens of liters per hour. NASA, on the
other hand, requires a much smaller production rate and volume capability, so other production technologies may be
preferred.
Maintaining sterility is more of a concern with occasional production, and the production system may be altered
to include components that are utilized only for limited durations to prevent contamination. NASA could use
technologies in a unique fashion to directly produce a solution while bypassing any storage of WFI. A future trade
study will evaluate the potential technologies, incorporating the results of small breadboard studies, and recommend
the type of system that should be developed for NASA’s Exploration missions.
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